MedTrace Logo

Augmenting Clozapine With Sertindole - SERCLOZ

NCT00345982 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2010-09-27

No results posted yet for this study

Summary

The purpose of the study is to determine whether addition of sertindole to clozapine treatment can improve psychosis or the metabolic side-effects of clozapine in patients with treatment-resistant schizophrenia.

Conditions

Interventions

DRUG

Serdolect

16 mg, 12 weeks

DRUG

placebo

placebo

Sponsors & Collaborators

  • H. Lundbeck A/S

    collaborator INDUSTRY

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Jimmi Nielsen, M.D. · Aalborg Psychiatric Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2010-09-30
Completion
2010-09-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00345982 on ClinicalTrials.gov